OncoPep, Inc.
To develop and commercialize targeted immuno-therapeutics which prevent the progression of cancer and prolong survival.
Boston, United States
4 employees
Series D
Total: $28.44M
Biotechnology, Health Care +1
General Information
Boston, United States
BounceWatch is an independent company data service, not affiliated with OncoPep, Inc.. To contact OncoPep, Inc., visit oncopep.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does OncoPep, Inc. compare?
A PDF of OncoPep, Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting OncoPep, Inc. soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
Discover More
United States Market
Biotechnology
About OncoPep, Inc.
Business keywords: immuno-therapeutics, cancer treatment, multi-peptide vaccine, T cell therapy, immunotherapeutics, immunotherapy, cancer research, tumor antigens, targeted therapy, biopharmaceuticals
Funding Rounds & Investors (6)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Series D | $11.00M | 3 |
|
10 Dec 2021 |
| Series B | $6.90M | 1 |
|
28 Aug 2014 |
| Venture Round | $3.04M | - |
|
06 May 2014 |
| Series A | $2.50M | - |
|
26 Apr 2012 |
| Series A | $500.00K | - |
|
13 Feb 2012 |
| Series A | $4.50M | - |
|
15 Apr 2011 |
OncoPep, Inc. Alternatives & Competitors
Tacalyx develops the next generation of anti-Cancer therapeutics in indications with high medical ne...
Delivering a cancer-free future
Targeted α-Particle Radiotherapy for Cancer
FAQ About OncoPep, Inc.
Source: BounceWatch company record for OncoPep, Inc., https://bouncewatch.com/company/oncopep-inc, updated 29 October 2024. When citing, please name BounceWatch and link this page.
